With a new study in the journal Science Bulletin, researchers at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University have ...

As of Friday, January 09, Coherus Oncology, Inc.’s CHRS share price has surged by 6.86%, which has investors questioning if ...

AI Foundation Model for Tumor and Immune Biology to Guide Precision Patient Selection for Novel Bifunctional OTP-01 BostonGene, the developer of the leading AI foundation model for tumor and immune ...

As of Wednesday, January 07, CytomX Therapeutics, Inc.’s CTMX share price has surged by 6.40%, which has investors questioning if this is right time to sell.

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Ottimo Pharma Limited ("Ottimo"), an innovative, ...

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and ...

Harbour BioMed inks long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates: Shanghai, China Tuesday, December 30, 2025, 13:00 Hr ...

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune ...

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to ...